132972-06-6

Basic information

• Product Name: trans-4-(2,4-dimethylphenyl)-4-oxo-2-butenoic acid
• Synonyms: trans-4-(2,4-dimethylphenyl)-4-oxo-2-butenoic acid
• CAS NO: 132972-06-6
• Molecular Weight: 204.225
• Mol File: 132972-06-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: trans-4-(2,4-dimethylphenyl)-4-oxo-2-butenoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-(2,4-dimethylphenyl)-4-oxo-2-butenoic acid(132972-06-6)
• EPA Substance Registry System: trans-4-(2,4-dimethylphenyl)-4-oxo-2-butenoic acid(132972-06-6)

Safety Data

• Hazardous Substances Data: 132972-06-6(Hazardous Substances Data)

Upstream product

• 108-31-6 maleic anhydride 
• 108-38-3 m-xylene 
• 110-16-7 maleic acid 

Downstream Products

• 1362038-16-1 6-(2,4-dimethylphenyl)-2-(4-(aminosulfonyl)phenyl)pyridazin-3(2H)-one 
• 77245-15-9 α-(Biscarbethoxy)methyl-β-(2',4'-dimethylbenzoyl)-β-benzylidenepropionic acid 
• 77239-55-5 2-[2-(2,4-Dimethyl-phenyl)-2-oxo-ethyl]-3-ethoxycarbonyl-succinic acid 
• 77239-73-7 6-Cyano-3-(2,4-dimethyl-phenyl)-5-hydrazono-cyclohex-3-enecarboxylic acid 

Relevant articles and documents

ENHANCER OF FERTILIZATION FUNCTION OF SPERM

An object of the present invention is to provide an agent for enhancing fertilization function of a mammal sperm, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient, and a method for enhancing fertilization function of a mammal sperm and a method for preparing a mammal fertilized egg, which use a low molecular compound which can be produced relatively easily and inexpensively. An agent comprising one or more compounds selected from the group consisting of compounds of the following formula (I0), formula (II), and formula (III), and physiologically acceptable salts thereof when R3 is OH is used as an agent for enhancing fertilization function of a mammal sperm.

Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR

In this study, a series of shikonin derivatives combined with benzoylacrylic had been designed and synthesized, which showed an inhibitory effect on both tubulin and the epidermal growth factor receptor (EGFR). In vitro EGFR and cell growth inhibition assay demonstrated that compound PMMB-317 exhibited the most potent anti-EGFR (IC50 = 22.7 nM) and anti-proliferation activity (IC50 = 4.37 μM) against A549 cell line, which was comparable to that of Afatinib (EGFR, IC50 = 15.4 nM; A549, IC50 = 6.32 μM). Our results on mechanism research suggested that, PMMB-317 could induce the apoptosis of A549 cells in a dose- and time-dependent manner, along with decrease in mitochondrial membrane potential (MMP), production of ROS and alterations in apoptosis-related protein levels. Also, PMMB-317 could arrest cell cycle at G2/M phase to induce cell apoptosis, and inhibit the EGFR activity through blocking the signal transduction downstream of the mitogen-activated protein MAPK pathway and the anti-apoptotic kinase AKT pathway; typically, such results were comparable to those of afatinib. In addition, PMMB-317 could suppress A549 cell migration through the Wnt/β-catenin signaling pathway in a dose-dependent manner. Additionally, molecular docking simulation revealed that, PMMB-317 could simultaneously combine with EGFR protein (5HG8) and tubulin (1SA0) through various forces. Moreover, 3D-QSAR study was also carried out, which could optimize our compound through the structure-activity relationship analysis. Furthermore, the in vitro and in vivo results had collectively confirmed that PMMB-317 might serve as a promising lead compound to further develop the potential therapeutic anticancer agents.

Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones

A series of novel pyridazinone derivatives bearing benzenesulfonamide moiety (2a-h) has been synthesized by the condensation of appropriate aroylacrylic acid and 4-hydrazinobenzenesulfonamide hydrochloride in ethanol. Five derivatives (2a, 2b, 2d, 2g and 2h) were evaluated for their anticancer activity toward human cancer cell lines by the National Cancer Institute. The 2h showed remarkable activity against SR (leukemia) and NCI-H522 (non-small cell lung) with a GI50 value of less than 0.1 μM. It also displayed good activity against leukemia (CCRF-CEM, HL-60 (TB), K-562, MOLT-4, RPMI-8226), non-small cell lung cancer (NCI-H460), colon (HCT-116, HCT-15, HT29, KMI2, SW-620), CNS (SF-295), melanoma (MALME-3M, M14, MDA-MB-435 SK-MEL-5), ovarian (OVCAR-3, NCI/ADR-RES) and breast (MCF7) cancer cell lines with a GI 50 less than 1.0 μM. The acute toxicity study of 2h indicated that it is well tolerated intra-peritoneally (400 mg/kg) by athymic nude mice. The 2h may possibly be used as lead compound for developing new anticancer agents.